Carfilzomib(Pfizer)은 Multiple Myeloma 표적 치료제로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consistent activation of the proteasome pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 97% (ClinicalTrials.gov NCT03412565). PK: t½ 1 h. 차별점: novel therapeutic targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consis.
Multiple Myeloma
Multiple Myeloma
Recruiting
CAR-T, and bispecific antibodies
novel therapeutic targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consis
targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consistent activation of the proteasome pathway
apoptosis in AC16 cardiomyocytes in a concentration- and time-dependent manner
biomarker and therapeutic target
resistance to bortezomib, highlighting IFITM1 as a potential prognostic biomarker and therapeutic target
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Carfilzomib(Pfizer)은 Multiple Myeloma 표적 치료제로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consistent activation of the proteasome pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 97% (ClinicalTrials.gov NCT03412565). PK: t½ 1 h. 차별점: novel therapeutic targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consis.
Multiple Myeloma
Multiple Myeloma
Recruiting
CAR-T, and bispecific antibodies
novel therapeutic targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consis
targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consistent activation of the proteasome pathway
apoptosis in AC16 cardiomyocytes in a concentration- and time-dependent manner
biomarker and therapeutic target
resistance to bortezomib, highlighting IFITM1 as a potential prognostic biomarker and therapeutic target
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.